-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aflibercept in Optic Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept in Optic Neuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aflibercept in Optic Neuropathy Drug Details: Aflibercept (Eylea / Eylea HD) is...
-
Product Insights
NewLeber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drugs In Development, 2024
Empower your strategies with our Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drugs In Development, 2024 report and make more profitable business decisions. Leber’s hereditary optic neuropathy (LHON) is an inherited form of vision loss. This condition usually begins in a person's teens or twenties; rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling, and clouding of vision. Predisposing factors include age,...
-
Product Insights
NewOptic Neuritis – Drugs In Development, 2024
Empower your strategies with our Optic Neuritis – Drugs In Development, 2024 report and make more profitable business decisions. Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. Symptoms include pain, vision loss, dyschromatopsia, Uhthoff’s phenomenon, and flashing lights. Risk factors include age and genetic mutations. The Optic Neuritis drugs in development market research report provide comprehensive information on the therapeutics under development for Optic Neuritis,...
-
Product Insights
NewOptic Neuropathy – Drugs In Development, 2024
Empower your strategies with our Optic Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling, and clouding of vision. Predisposing factors include age, smoking, alcohol, cancer treating drugs, stress related chemicals, some antibiotics, and cyanogens. The Optic Neuropathy drugs in development market research report provide comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage...
-
Product Insights
NewOptic Nerve Injury – Drugs In Development, 2024
Empower your strategies with our Optic Nerve Injury – Drugs In Development, 2024 report and make more profitable business decisions. Optic Nerve Injury or optic neuropathy is a common cause of vision loss occurring as a result of damage to the optic nerve. Optic nerve is a group or bundle of nerve fibers that carry out the communication between the eyes and brain. Trauma can be a common cause or complicated cases of diabetic retinopathy can also cause ONI. Neuroimaging studies...
-
Product Insights
NewDynamin Like 120 kDa Protein Mitochondrial – Drugs In Development, 2024
The Dynamin Like 120 kDa Protein Mitochondrial pipeline drugs market research report outlays comprehensive information on the Dynamin Like 120 kDa Protein Mitochondrial targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Ophthalmology which include indications of Ophthalmology, and Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy). It also reviews key players involved in Dynamin Like 120 kDa Protein...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AXER-204 in Chronic Spinal Cord Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AXER-204 in Chronic Spinal Cord Injury report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AXER-204 in Chronic Spinal Cord Injury Drug Details: AXER-204...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACT-001 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACT-001 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACT-001 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: ACT-001...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ST-266 in Necrotizing Enterocolitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ST-266 in Necrotizing Enterocolitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ST-266 in Necrotizing Enterocolitis Drug Details: ST-266 is under development for...
-
Product Insights
NewBeta Nerve Growth Factor – Drugs In Development, 2024
The Beta Nerve Growth Factor pipeline drugs market research report outlays comprehensive information on the Beta Nerve Growth Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Ophthalmology, Cardiovascular, and Hematological Disorders which include indications of Cancer Pain, Pain, Glaucoma, Optic Nerve Injury, Myocardial Infarction, Cardiac Arrest, and Sickle Cell Disease. It also reviews...